Coya Therapeutics reports positive proof-of-concept study results in Frontotemporal Dementia

Coya Therapeutics, Inc.

9-patient open-label study of low-dose IL-2 + CTLA4-Ig showed no serious adverse events over 22 weeks.
Treg suppressive function and percentage significantly increased from week 2 through week 22.
MOCA scores stable (baseline 13.5, week 22: 14) and CDR-FTLD stable (4.8 vs 5.5), indicating no cognitive decline.
Study led by Houston Methodist Neurological Institute; funded by Peggy and Gary Edwards Endowment Fund.
Common adverse event was mild injection-site erythema (33.3%); all resolved spontaneously.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.